{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T03:46:29Z","timestamp":1782359189224,"version":"3.54.5"},"reference-count":49,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100019717","name":"AstraZeneca Farmaceutica Spain SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","revespcardiol.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.rec.2025.12.016","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:57:45Z","timestamp":1766509065000},"page":"618-630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictors of poor prognosis in a large cohort of patients with hereditary cardiac transthyretin amyloidosis"],"prefix":"10.1016","volume":"79","author":[{"given":"Tom\u00e1s","family":"Ripoll-Vera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"de Frutos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Gonz\u00e1lez-Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Jos\u00e9","family":"Manovel-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Zorio-Grima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Teresa","family":"Bosch-Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Garc\u00eda-Pinilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Robledo-I\u00f1arritu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Limeres-Freire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Garc\u00eda-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Gallego-Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Espinosa-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"L\u00f3pez-Aguilera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Mac\u00edas-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Valverde-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xabier","family":"Arana-Achaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Isabel","family":"Rodr\u00edguez-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgardo","family":"Alania-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 \u00c1ngel","family":"Urbano-Moral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Larra\u00f1aga-Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coloma","family":"Tir\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Alejandra","family":"Restrepo-C\u00f3rdoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainara","family":"Lozano-Bahamonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Ruiz-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Revilla-Mart\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 J.","family":"Onaindia-Gandarias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Camacho-Jurado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luisa","family":"Pe\u00f1a-Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cordero-Pereda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idaira Famara","family":"Hern\u00e1ndez-Baldomero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo Elpidio","family":"Garc\u00eda-Granja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Ruiz-Bustillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"\u00c1lvarez-Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rec.2025.12.016_bib0250","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11897-013-0182-4","article-title":"Novel Drugs Targeting Transthyretin Amyloidosis","volume":"11","author":"Hanna","year":"2014","journal-title":"Current Heart Failure Reports."},{"key":"10.1016\/j.rec.2025.12.016_bib0255","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","article-title":"Evolving landscape in the management of transthyretin amyloidosis","volume":"47","author":"Hawkins","year":"2015","journal-title":"Ann Med."},{"key":"10.1016\/j.rec.2025.12.016_bib0260","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jns.12153","article-title":"Red-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy","volume":"21","author":"Concei\u00e7\u00e3o","year":"2016","journal-title":"J Peripher Nerv Syst."},{"key":"10.1016\/j.rec.2025.12.016_bib0265","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","article-title":"Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy","volume":"268","author":"Adams","year":"2021","journal-title":"J Neurol."},{"key":"10.1016\/j.rec.2025.12.016_bib0270","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","article-title":"Disease profile differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective","volume":"34","author":"Rapezzi","year":"2012","journal-title":"Eur Heart J."},{"key":"10.1016\/j.rec.2025.12.016_bib0275","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.rec.2025.12.016_bib0280","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1136\/heartjnl-2012-301924","article-title":"Cardiac transthyretin amyloidosis","volume":"98","author":"Dungu","year":"2012","journal-title":"Heart."},{"key":"10.1016\/j.rec.2025.12.016_bib0285","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/13506129.2015.1019610","article-title":"amyloidosis: a single-institution experience with 266 patients","volume":"22","author":"Swiecicki","year":"2015","journal-title":"Amyloid."},{"key":"10.1016\/j.rec.2025.12.016_bib0290","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","article-title":"Cardiac phenotype clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant","volume":"33","author":"Sattianayagam","year":"2011","journal-title":"Eur Heart J."},{"key":"10.1016\/j.rec.2025.12.016_bib0295","doi-asserted-by":"crossref","first-page":"E2403","DOI":"10.1002\/humu.22619","article-title":"Online registry for mutations in hereditary amyloidosis including nomenclature recommendations","volume":"35","author":"Rowczenio","year":"2014","journal-title":"Hum Mutat."},{"key":"10.1016\/j.rec.2025.12.016_bib0300","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13023-022-02359-w","article-title":"Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update","volume":"17","author":"Dispenzieri","year":"2022","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.rec.2025.12.016_bib0305","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/13506129.2022.2065191","article-title":"Hereditary transthyretin amyloidosis in Sweden: Comparisons between a non-endemic and an endemic region","volume":"29","author":"Samuelsson","year":"2022","journal-title":"Amyloid."},{"key":"10.1016\/j.rec.2025.12.016_bib0310","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13023-017-0726-x","article-title":"Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm","volume":"13","author":"Sekijima","year":"2018","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.rec.2025.12.016_bib0315","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/jns.12259","article-title":"The genetic heterogeneity of hereditary transthyretin amyloidosis in a sample of the Brazilian population","volume":"23","author":"Lavigne-Moreira","year":"2018","journal-title":"J Peripher Nerv Syst."},{"key":"10.1016\/j.rec.2025.12.016_bib0320","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1750-1172-9-29","article-title":"Epidemiology of transthyretin-associated familial amyloid polyneuropathy in the Majorcan area: Son Ll\u00e0tzer Hospital descriptive study","volume":"9","author":"Rein\u00e9s","year":"2014","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.rec.2025.12.016_bib0325","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.recesp.2021.07.007","article-title":"Characterization of hereditary transthyretin cardiac amyloidosis in Spain","volume":"75","author":"\u00c1lvarez Rubio","year":"2022","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rec.2025.12.016_bib0330","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J."},{"key":"10.1016\/j.rec.2025.12.016_bib0335","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s13023-023-02910-3","article-title":"Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan","volume":"18","author":"Ando","year":"2023","journal-title":"Brazil, and Portugal. Orphanet J Rare Dis."},{"key":"10.1016\/j.rec.2025.12.016_bib0340","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/jnnp-2021-327909","article-title":"Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis","volume":"93","author":"Carroll","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.rec.2025.12.016_bib0345","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","article-title":"Vutrisiran: First Approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs."},{"key":"10.1016\/j.rec.2025.12.016_bib0350","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.recesp.2017.09.006","article-title":"Cardiac Involvement in a Patient Cohort With Val30Met Mutation Transthyretin Amyloidosis","volume":"72","author":"Ripoll-Vera","year":"2019","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rec.2025.12.016_bib0355","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.recesp.2019.12.017","article-title":"Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center","volume":"74","author":"L\u00f3pez-Sainz","year":"2021","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rec.2025.12.016_bib0360","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40120-021-00267-y","article-title":"A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey","volume":"10","author":"Gonzalez-Moreno","year":"2021","journal-title":"Neurol Ther."},{"key":"10.1016\/j.rec.2025.12.016_bib0365","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation."},{"key":"10.1016\/j.rec.2025.12.016_bib0370","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/13506129.2020.1744553","article-title":"The sensitivity of DPD scintigraphy to detect transthyretin cardiac amyloidosis in V30M mutation depends on the phenotypic expression of the disease","volume":"27","author":"Azevedo Coutinho","year":"2020","journal-title":"Amyloid."},{"key":"10.1016\/j.rec.2025.12.016_bib0375","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation."},{"key":"10.1016\/j.rec.2025.12.016_bib0380","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jaccao.2022.07.007","article-title":"Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms","volume":"4","author":"Gonzalez-Lopez","year":"2022","journal-title":"JACC CardioOncol."},{"key":"10.1016\/j.rec.2025.12.016_bib0385","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214363","article-title":"Prognostic value of NT-proBNP added to clinical parameters to predict two-year prognosis of chronic heart failure patients with mid-range and reduced ejection fraction - A report from FAR NHL prospective registry","volume":"14","author":"Spinar","year":"2019","journal-title":"PLoS One."},{"key":"10.1016\/j.rec.2025.12.016_bib0390","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00415-019-09602-8","article-title":"Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis","volume":"267","author":"Gonz\u00e1lez-Duarte","year":"2020","journal-title":"J Neurol."},{"key":"10.1016\/j.rec.2025.12.016_bib0395","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.121.003356","article-title":"Prevalence and Outcomes of p.Val142Ile TTR Amyloidosis Cardiomyopathy: A Systematic Review","volume":"14","author":"Chandrashekar","year":"2021","journal-title":"Circ Genom Precis Med."},{"key":"10.1016\/j.rec.2025.12.016_bib0400","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1469-1809.2008.00439.x","article-title":"On the origin of the transthyretin Val30Met familial amyloid polyneuropathy","volume":"72","author":"Zaros","year":"2008","journal-title":"Ann Hum Genet."},{"key":"10.1016\/j.rec.2025.12.016_bib0405","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/eurheartj\/ehz173","article-title":"Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"43","author":"Damy","year":"2019","journal-title":"Eur Heart J."},{"key":"10.1016\/j.rec.2025.12.016_bib0410","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2025.12.016_bib0415","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail."},{"key":"10.1016\/j.rec.2025.12.016_bib0420","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","article-title":"Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review","volume":"10","author":"Rozenbaum","year":"2021","journal-title":"Cardiol Ther."},{"key":"10.1016\/j.rec.2025.12.016_bib0425","first-page":"1299","article-title":"Native T1 Mapping Extracellular Volume Mapping, and Late Gadolinium Enhancement in Cardiac Amyloidosis: A Meta-Analysis","volume":"13","author":"Pan","year":"2020","journal-title":"JACC: Cardiovascular Imaging."},{"issue":"sup1","key":"10.1016\/j.rec.2025.12.016_bib0430","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/13506129.2016.1272453","article-title":"Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful?","volume":"24","author":"aus dem Siepen","year":"2017","journal-title":"Amyloid."},{"key":"10.1016\/j.rec.2025.12.016_bib0435","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jacc.2019.01.035","article-title":"High Prevalence of Intracardiac Thrombi in Cardiac Amyloidosis","volume":"73","author":"Martinez-Naharro","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2025.12.016_bib0440","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jaccao.2021.06.006","article-title":"ATTR Amyloidosis: Current and Emerging Management Strategies: JACC: CardioOncology State-of-the-Art Review","volume":"3","author":"Griffin","year":"2021","journal-title":"JACC CardioOncol."},{"key":"10.1016\/j.rec.2025.12.016_bib0445","series-title":"Tafamidis [Updated 2023 May 29]. In: StatPearls [Internet]. Treasure Island (FL):","author":"Verma","year":"2025"},{"key":"10.1016\/j.rec.2025.12.016_bib0450","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPs). Summary of Product Characteristics Vyndaqel 61mg. Available at: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1110717003\/FT_1110717003.html. Accessed 1 July 2024."},{"key":"10.1016\/j.rec.2025.12.016_bib0455","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rec.2025.12.016_bib0460","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPs). Summary of Product Characteristics Onpattro. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1181320001\/FT_1181320001.html. Accessed 1 July 2024."},{"key":"10.1016\/j.rec.2025.12.016_bib0465","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPs). Summary of Product Characteristics Tegsedi. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1181296002\/ft_1181296002.html#1. Accessed 1 July 2024."},{"key":"10.1016\/j.rec.2025.12.016_bib0470","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA."},{"key":"10.1016\/j.rec.2025.12.016_bib0475","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rec.2025.12.016_bib0480","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/pace.14023","article-title":"Primary prevention implantable cardioverter-defibrillators in transthyretin cardiac amyloidosis","volume":"43","author":"Donnellan","year":"2020","journal-title":"Pacing Clin Electrophysiol."},{"key":"10.1016\/j.rec.2025.12.016_bib0485","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3390\/brainsci11050545","article-title":"Use of Drugs for ATTRv Amyloidosis in the Real World: How Therapy Is Changing Survival in a Non-Endemic Area","volume":"11","author":"Russo","year":"2021","journal-title":"Brain Sciences."},{"issue":"Suppl 1","key":"10.1016\/j.rec.2025.12.016_bib0490","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","article-title":"First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy","volume":"29","author":"Adams","year":"2016","journal-title":"Curr Opin Neurol."}],"container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585725003639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585725003639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T03:00:25Z","timestamp":1782356425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1885585725003639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1885585725003639"],"URL":"https:\/\/doi.org\/10.1016\/j.rec.2025.12.016","relation":{},"ISSN":["1885-5857"],"issn-type":[{"value":"1885-5857","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of poor prognosis in a large cohort of patients with hereditary cardiac transthyretin amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rec.2025.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.recesp.2025.12.013","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Cardiolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}